Enovis (ENOV) Cash from Investing Activities (2010 - 2026)
Enovis' (ENOV) quarterly Cash from Investing Activities came in at -$53.1 million in Q2 2026, up 12.27% year-on-year from -$47.3 million in Q2 2025, and down 308.71% on a QoQ basis from -$13.0 million in Q4 2025.
Enovis (ENOV) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Enovis (ENOV) has 17 years of Cash from Investing Activities data on file, last reported at -$53.1 million in Q2 2026.
- On a quarterly basis, Cash from Investing Activities rose 12.27% year-over-year to -$53.1 million in Q2 2026; TTM through Apr 2026 was -$171.9 million, a 21.18% increase from a year earlier, with the FY2025 full-year figure at -$179.4 million, up 81.23% from the prior year.
- Cash from Investing Activities for Q2 2026 stood at -$53.1 million, down from -$13.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ENOV reached as high as -$13.0 million in Q4 2025 and fell as low as -$797.8 million in Q1 2024.
- Historically, Cash from Investing Activities has averaged -$94.5 million across 5 years, with a median of -$53.1 million in 2026.
- Across the five-year window, Cash from Investing Activities tumbled 2220.32% in 2024 and jumped 92.41% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$37.1 million in 2022, then slumped by 60.14% to -$59.4 million in 2023, then rose by 2.51% to -$57.9 million in 2024, then soared by 77.56% to -$13.0 million in 2025, then plunged by 308.71% to -$53.1 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$53.1 million in Q2 2026, -$13.0 million in Q4 2025, and -$56.1 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Enovis | 1.61 Bn | 1.58 Bn | 365.49 Mn | -53.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -53.10 Mn |
| Apr 3, 2026 | -53.10 Mn |
| Dec 31, 2025 | -12.99 Mn |
| Dec 31, 2025 | -12.99 Mn |
| Oct 3, 2025 | -56.06 Mn |
| Oct 3, 2025 | -56.06 Mn |
| Jul 4, 2025 | -49.80 Mn |
| Jul 4, 2025 | -49.80 Mn |
| Apr 4, 2025 | -60.52 Mn |
| Apr 4, 2025 | -60.52 Mn |
| Dec 31, 2024 | -57.88 Mn |
| Dec 31, 2024 | -57.88 Mn |
| Sep 27, 2024 | -58.42 Mn |
| Sep 27, 2024 | -58.42 Mn |
| Jun 28, 2024 | -41.33 Mn |
| Jun 28, 2024 | -41.33 Mn |
| Mar 29, 2024 | -797.84 Mn |
| Mar 29, 2024 | -797.84 Mn |
| Dec 31, 2023 | -59.37 Mn |
| Dec 31, 2023 | -59.37 Mn |